{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-24-000081","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.852318+00:00","generated_at":"2026-05-31T04:21:45.445236+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Context Therapeutics stockholders approve doubling authorized shares to 200M","bullets":["Stockholders voted 42,389,461 for, 790,853 against, 71,655 abstain to increase authorized common shares to 200,000,000.","Authorization increased from 100,000,000 to 200,000,000 shares of common stock.","Special Meeting held September 17, 2024; quorum of 43,251,969 shares (57.67%) present.","Proposal also included approval of adjournments if needed, passed with 42,447,035 votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-24-000081","json":"https://secwatch.observer/filing/0001842952-24-000081.json","markdown":"https://secwatch.observer/filing/0001842952-24-000081.md","text":"https://secwatch.observer/filing/0001842952-24-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000081/0001842952-24-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295224000081/cntx-20240917.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:21:45.445236+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}